Maravai LifeSciences stock: TD Cowen starts coverage at USD 9.00 for Maravai LifeSciences stock

Published on 10/23/2026 at 00:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 51.44 million, up 9.00 percent year over year. November 4, 2026 is the next results date for Maravai LifeSciences stock.

Coverage and results dates

TD Cowen initiated coverage with a USD 9.00 target on October 5, 2026.
Second-quarter revenue reached USD 51.44 million, up 9.00 percent year over year.
Maravai LifeSciences plans to release third-quarter results on November 4, 2026.

MRVI, US56600D1072, Illustration mit AI erstellt.

TD Cowen initiated coverage of Maravai LifeSciences with a USD 9.00 price target and a Buy rating on October 5, 2026, according to Investing.com. The analyst case centers on returning CleanCap growth and the conversion of non-COVID mRNA programs from discovery into higher-value GMP products.

Three dates shape MRVI

The recent timeline combines an analyst catalyst with operating evidence. On October 5, 2026, TD Cowen set its USD 9.00 target. On October 13, 2026, Benzinga published management commentary on second-quarter results, including revenue of USD 51.44 million, a 9.00 percent year-over-year increase, and adjusted gross margin of 58.90 percent. On October 14, 2026, Maravai announced the date for its next results release.

The earnings call also showed a sharper contrast between growth and profitability. TriLink revenue rose 12.00 percent year over year in the second quarter, while Cygnus revenue increased 3.00 percent. Adjusted EBITDA reached USD 8.70 million, an improvement of USD 19.10 million, and management maintained 2026 revenue guidance of USD 205.00 million to USD 215.00 million while raising adjusted EBITDA guidance to USD 33.00 million to USD 35.00 million, as reported by Yahoo Finance.

What supports the target?

TD Cowen's thesis depends on commercial conversion rather than a single quarter. Management said GMP consumables grew 55.00 percent year over year in the second quarter, while 125 customers were using Motail after its first year on the market. That product adoption provides a measurable link between discovery activity and a potential future GMP revenue stream.

The balance sheet adds a second factor. Maravai ended the second quarter with USD 70.10 million in cash and USD 147.10 million in debt, while the company extended debt maturities to 2032. The counter-factor is execution: large GMP and CDMO orders remain program-driven, so their timing can shift between quarters.

Next results date

Yahoo Finance reported on October 14, 2026, that Maravai plans to release third-quarter financial and operating results after the market close on November 4, 2026, followed by a conference call at 5:00 p.m. ET. That date is the next scheduled test of the revenue range and the raised profitability outlook.

Market value and trading date

Maravai LifeSciences had a USD 2.0 billion market capitalization and a USD 2.54 to USD 9.42 52-week range as of October 22, 2026. The stock was last quoted at USD 7.07 on October 22, 2026 at 4:00 p.m. ET on Nasdaq. The further course of trading is shown by the continuously updated real-time quote of Maravai LifeSciences stock.